Rani Therapeutics Holdings RANI
NASDAQ RANI
$0.81 +0.02 (+2.02%)
As of: Oct 2, 2026 · 10:08 AM EDT

Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2026)

Updated

Rani Therapeutics Holdings' Liabilities and Shareholders Equity was $60.84 million in Q2 2026, up 260.1% from $16.9 million a year earlier and up 17.3% from the prior quarter.

Analysis

Rani Therapeutics Holdings (RANI) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends

At the end of FY2025, Liabilities and Shareholders Equity at Rani Therapeutics Holdings came in at $58.62 million, up 60.0% from FY2024.

  • Liabilities and Shareholders Equity shows a five-year compound annual growth rate of -5.9% (FY2020 to FY2025).
  • In earlier years, Liabilities and Shareholders Equity was $36.63 million in FY2024 (-36.7%), $57.92 million in FY2023 (-46.4%), $108.03 million in FY2022 (-13.0%) and $124.21 million in FY2021 (+56.4%).
  • The Q2 2026 figure marks the highest quarterly Liabilities and Shareholders Equity since Q3 2023.
  • Compared with a year earlier, Liabilities and Shareholders Equity has increased for three straight quarters, with growth averaging 20.9% over the last eight quarters.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q2 2026 (growth of 260.1%); the worst was Q3 2025 (a decline of 76.7%).
  • Per Business Quant data, RANI's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $51.88 million (Q1 2026), $58.62 million (Q4 2025) and $10.14 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Rani Therapeutics Holdings 147.86 Mn 156.61 Mn - 60.84 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 60.84 Mn
Mar 31, 2026 51.88 Mn
Dec 31, 2025 58.62 Mn
Sep 30, 2025 10.14 Mn
Jun 30, 2025 16.90 Mn
Mar 31, 2025 24.13 Mn
Dec 31, 2024 36.63 Mn
Sep 30, 2024 43.54 Mn
Jun 30, 2024 43.73 Mn
Mar 31, 2024 53.51 Mn
Dec 31, 2023 57.92 Mn
Sep 30, 2023 70.44 Mn
Jun 30, 2023 83.51 Mn
Mar 31, 2023 96.45 Mn
Dec 31, 2022 108.03 Mn
Sep 30, 2022 108.20 Mn
Jun 30, 2022 104.34 Mn
Mar 31, 2022 115.31 Mn
Dec 31, 2021 124.21 Mn
Sep 30, 2021 136.96 Mn
API Access

Rani Therapeutics Holdings Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=RANI&period=max&api_key=YOUR_API_KEY